Summary of 2020
The year 2020 was the year of COVID-19. It was also Inven2’s tenth anniversary. However, it was also a year in which much value was created from the research carried out at the University of Oslo, Oslo University Hospital and the other health trusts in the South-Eastern Norway Regional Health Authority.
Gain insight into success stories, strategic activities and key figures.
Most protein-based therapeutics must be injected to be effective. That is both stressful for the patient and costly for the healthcare system....
Zelluna Immunotherapy receives NOK 83 million from investors and the Research Council of Norway to continue its work on a new form of cancer...
The Dutch medical device company SJJ Solutions, the Department of Ophthalmology at Oslo University Hospital and the Laboratory of Adaptive Immunity...
Inven2’s core business is innovation. We contribute in the process of commersialising good ideas from talented researchers, turning them into products and services that make a difference.
Inven2 work closely with hospitals and companies to make sure clinical studies are completed quick and efficient, to the best for Norwegian patients.
Key figures 2010 – 2020
# Ideas evaulated (DOFI)
# Companies established
# Licence agreements
# New patent applications
MNOK transferred back to research, innovation and inventors
# Clinical Trials managed